Forte Bio-Pharma

Name

Forte Bio-Pharma

Legal name

Forte Bio-Pharma LLC.

Website

https://fortebiopharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Pain management medications
• Opioid analgesics
• Prescription drug development
• Muscle relaxant drugs

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel, Infrastructure

Revenue model

1. Prescription Pharmaceutical Sales: Revenue generated from the sale of branded prescription pain medications (NALOCET, Prolate, Tanlor) distributed through pharmacies to patients with valid prescriptions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Forte Bio-Pharma is a specialty pharmaceutical company that in-licenses, develops, and commercializes FDA-approved prescription pain medications. Its product portfolio includes NALOCET® and Prolate® (oxycodone/acetaminophen combinations at unique dosage strengths) and Tanlor® (methocarbamol tablets for musculoskeletal conditions), distributed through a preferred pharmacy partner network to healthcare providers.

Product overview

Forte Bio-Pharma is a specialty pharmaceutical company focused on the in-licensing, development, and commercialization of pain medications. The company offers three FDA-approved prescription products: NALOCET® (the lowest available combination of oxycodone and acetaminophen), Prolate® (oxycodone/acetaminophen available in 3 doses), and Tanlor® (Methocarbamol, a muscle relaxant). These products are distributed through pharmacy partners and target healthcare providers seeking unique dosage options for pain management and musculoskeletal conditions.

Differentiator

Problem solved

Functional benefit

Brands

• NALOCET®: Oxycodone/Acetaminophen combination product - the lowest available combination of oxycodone and acetaminophen
• Prolate®
• Tanlor®

Products and services

• NALOCET® (Oxycodone/Acetaminophen) Prescription opioid/acetaminophen combination tablet offering the lowest available dosage combination of oxycodone and acetaminophen for healthcare providers treating pain conditions.
• Prolate® (Oxycodone/Acetaminophen) Prescription opioid/acetaminophen combination tablet available in 3 different dose strengths, providing healthcare providers with multiple dosage options for pain management.
• Tanlor® (Methocarbamol Tablets, USP) Prescription muscle relaxant tablet containing methocarbamol, indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Quantifiable outcome

• Unique low-dose formulation available in the market
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Preferred Pharmacy ProviderscoreChannel Partner/ Reseller/ DistributorForte Bio-Pharma partners with pharmacies to become preferred providers for dispensing its prescription pain medications. Partner pharmacies gain access to copay card programs, product ordering support, and assistance in locating preferred providers for patients.
• Business PartnersminorStrategic or Co-development PartnerForte Bio-Pharma welcomes business partnering opportunities with companies (non-pharmacy) interested in exploring partnership prospects. Contact available via phone (833-336-7837) or email.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management with branded abuse-deterrent and differentiated opioid products such as Xtampza ER and Nucynta. Most directly comparable to Forte given its specialty-pain focus, small commercial footprint, and reliance on differentiated formulations of mature molecules.
• Assertio Therapeutics: Specialty pharma focused on non-opioid and pain therapies (formerly Depomed). Comparable to Forte as a small, focused pain/specialty company commercializing differentiated formulations of established molecules to a similar prescriber base.
• Rhodes Pharmaceuticals: Subsidiary of Perrigo that markets generic and branded opioid analgesic products including oxycodone/acetaminophen combinations. Direct competitor to Forte's NALOCET and Prolate lines with overlapping molecule portfolio and distribution channels.

Broad incumbents

• Endo International: Diversified specialty pharma with a large pain management franchise (formerly including Opana ER and Percocet lines) and broader generics business. Comparable as a pain-focused commercial pharma, though substantially larger and more diversified than Forte.
• Mallinckrodt Pharmaceuticals: Specialty pharma with significant branded and generic opioid analgesics portfolio and broader specialty therapeutics. Comparable product overlap with Forte on Schedule II/III opioid combinations, though at much greater scale and broader therapeutic breadth.
• Apotex: Large Canadian-based generic pharmaceutical manufacturer with US generic opioid and pain portfolios. Comparable on molecule overlap (oxycodone/acetaminophen and methocarbamol) and channel (US pharmacy distribution), though at vastly greater scale.
• Purdue Pharma: Established opioid pharmaceutical company with historic leadership in oxycodone-based pain products (OxyContin). Comparable to Forte through direct overlap in oxycodone-based pain medications, though Purdue is under bankruptcy restructuring and operates at very different scale.
• Amneal Pharmaceuticals: Generic and specialty pharmaceutical manufacturer with a meaningful pain franchise including oxycodone/acetaminophen products. Comparable to Forte on molecule overlap, though Amneal operates at far greater scale across many therapeutic categories.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a substantial US pain portfolio including generic oxycodone/acetaminophen combinations. Comparable molecule overlap and pharmacy distribution channels, but operates across a far broader therapeutic range at global scale.

Emerging players

• Scilex Holding: Emerging specialty pharma focused on non-opioid pain and specialty pain products (e.g., ZTlido, SP-103). Comparable to Forte as a smaller, focused pain/specialty player pursuing differentiation in a challenging opioid environment, though with a non-opioid portfolio emphasis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/forte-bio-pharma-llc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forte Bio-Pharma